Overview of Monteka

Property	Description
Active ingredient	Montelukast sodium
Form	Tablet, Chewable Tablet, Oral Granule
Pharmacological Class	Leukotriene Receptor Antagonist (LTRA)
Origin	Synthetic Compound
Route of Administration	Oral

What Type of Medicine is Monteka?

Monteka is a specific trade name for a single-ingredient, prescription-only medication whose active substance is the chemically synthesized compound Montelukast sodium (INN). This medication is classified as a Leukotriene Receptor Antagonist (LTRA), a specific type of anti-asthmatic and antiallergic modifying agent.

Montelukast is clinically recognized for its systemic, oral activity, setting it apart from many inhaled respiratory therapies. Its pharmacological identity defines it as a non-steroidal agent that selectively inhibits the action of cysteinyl leukotrienes at the CysLT1 receptor.

Composition and Available Forms (Tablet, Chewable, Granule)

Monteka contains Montelukast as the sodium salt, delivered in solid forms intended for oral administration. The medicine is manufactured in various presentations, notably the flavored chewable tablet and the oral granule formulations. These diverse forms—tablet, chewable tablet, and granule—all deliver the same active substance and are designated for the oral route of administration, offering necessary flexibility, particularly for the pediatric patient group.

General Purpose as a Leukotriene Modifying Agent

The primary therapeutic purpose of Montelukast is to help reduce and prevent inflammatory reactions in the respiratory system by specifically targeting leukotrienes. By blocking these inflammatory mediators from binding to receptors in the airways, the drug helps inhibit associated physiological effects such as swelling and smooth muscle contraction.

This consistent, preventive mechanism allows the drug to function as a long-term control agent, contributing to the stabilization of chronic conditions where airway inflammation is a core pathological factor. This function positions Monteka as a foundational, non-acute therapy aimed at sustaining proper respiratory function by modifying the body's ongoing inflammatory response.

Regulatory References

Montelukast Overview, MedlinePlus

What side effects are possible with Monteka?

Possible Side Effects and Safety Information

The safety profile of Montelukast (Monteka) is documented based on clinical studies and post-marketing surveillance, classifying reported effects by frequency as consistent with regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reaction is upper respiratory infection, classified as Very Common (occurring in at least 1 in 10 individuals). Effects classified as Common (at least 1 in 100 individuals) include headache, abdominal pain, fever, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Additionally, rash and elevations in liver enzymes (ALT, AST) are listed as common.

Key Safety Warnings

Official labeling contains warnings regarding serious Neuropsychiatric Events, which have been reported across all age groups. These events include mood and behavior changes such as suicidal thoughts and behavior, aggression, agitation, depression, and sleep disturbances. Reports indicate these symptoms may persist or emerge even after treatment is stopped.

Very Rare reports also include systemic conditions such as Churg-Strauss syndrome (CSS), a vasculitic syndrome often seen in association with the reduction or withdrawal of oral corticosteroid therapy, and hepatitis (liver inflammation).

Safety Constraints and Considerations

Montelukast is indicated only for long-term control and prevention and must not be used to treat acute asthma attacks. For patients with aspirin-sensitive asthma, the regulatory constraint is that they must continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while receiving this therapy. The chewable tablet formulation contains aspartame, a source of phenylalanine, which is a required consideration for individuals with phenylketonuria (PKU).

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory guidance for Monteka (Montelukast sodium) overdose emphasizes a response centered on supportive management, as no specific antidote is known. Official reports submitted to government health authorities describe a core set of clinical findings observed in overdose cases, involving both adult and pediatric patients.

Documented Clinical Manifestations

Overdose presentations documented in regulatory sources included a set of central nervous system and gastrointestinal findings:

Somnolence (drowsiness) and Headache
Psychomotor hyperactivity
Abdominal pain and Vomiting
Thirst

In the majority of these reports, the observed clinical and laboratory findings were consistent with the drug’s known safety profile, and severe or life-threatening outcomes were generally not described.

Required Emergency Action and Management

In the event of suspected overdosage, it is required to seek immediate medical attention. Because no specific pharmacological antidote exists, regulatory guidance mandates that treatment must consist of employing the usual supportive measures and continuous clinical monitoring of the patient’s status. Management may also include instituting symptomatic therapy and procedural steps, such as removing unabsorbed material from the gastrointestinal tract, if deemed clinically necessary.

Therapeutic Uses of Monteka

What Monteka Treats: Main Uses and Benefits

Monteka is a specialized controller medication generally used for the long-term management and prevention of chronic symptoms related to specific respiratory and allergic conditions. This medication is applied across three core therapeutic areas.

The primary therapeutic applications involve the long-term control of chronic asthma, the symptomatic relief of allergic rhinitis (both seasonal and perennial), and the prevention of exercise-induced breathing difficulty.

Chronic Asthma and Allergic Relief

Monteka is commonly prescribed for the daily management of symptoms associated with mild-to-moderate persistent asthma, playing a role in managing symptoms that create noticeable physiological strain, such as wheezing, chronic coughing, and chest tightness. It is also applied to address the symptomatic discomfort of allergic rhinitis, relevant for managing clusters of symptoms like nasal congestion and sneezing. This continuous, preventive support is relevant for easing the overall symptom load and may assist with maintaining functional stability.

“This medication is primarily used to help prevent symptoms, supporting the patient during difficult episodes and helping with participation in routine activities.”

Situational Prevention

A distinct application is the prevention of exercise-induced bronchoconstriction (EIB). Used before physical exertion, this generally provides a relevant situational benefit: it may assist with maintaining functional stability, supporting the patient during difficult episodes, and helping with participation in routine activities.

Quick Fact: Relief for Respiratory and Allergic Discomfort Monteka is commonly used to help patients manage symptoms that interfere with daily functioning across both the lower respiratory tract (asthma) and the upper respiratory tract (allergic rhinitis).

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Monteka?

This medicine is restricted to certain populations as defined by regulatory documents, primarily based on age, acute conditions, and known sensitivities.

Contraindicated Populations

Classification	Population Group	Condition/Setting
Prohibited	Patients with hypersensitivity	Known allergy to Montelukast or any formulation component.
Prohibited	Patients in acute distress	Treatment of acute asthma attacks (must not be used).
Restricted	Patients with PKU	Must be advised that chewable tablets contain phenylalanine.

Age-Related Eligibility (Minimum Thresholds)

Official guidelines set differing minimum ages for use depending on the condition:

Chronic Asthma: Eligible for patients 12 months of age and older.
Perennial Allergic Rhinitis: Eligible for patients 6 months of age and older.
Exercise-Induced Bronchoconstriction: Eligible for patients 6 years of age and older.

Special Population Status

Renal/Hepatic Impairment: Patients with renal impairment or mild-to-moderate hepatic impairment are generally eligible, as dose adjustment is not required.
Pregnancy and Lactation: Use during pregnancy and breastfeeding is generally permitted when the clinical benefit to the mother is considered clearly essential, as Montelukast is present in human milk in very small amounts.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific interactions for Montelukast (marketed as Monteka) based primarily on its metabolism by cytochrome P450 enzymes (CYP2C8, CYP2C9, and CYP3A4). These interactions may result in an altered concentration of Montelukast or the co-administered drug, requiring clinical attention and monitoring.

Interacting Product Category	Specific Examples Listed	Practical Constraint or Requirement
Enzyme Inducers	Carbamazepine, Rifampin, Phenobarbital	Co-administration may decrease Montelukast plasma concentrations, which could lead to reduced efficacy. Monitoring for loss of therapeutic effect is advised by regulatory documents.
CYP2C8 Inhibitors	Gemfibrozil	Co-administration may significantly increase the systemic exposure of Montelukast, requiring monitoring for increased effects.
Oral Anticoagulants	Warfarin	Montelukast does not appear to have clinically important effects on the pharmacokinetics of Warfarin, but close monitoring of coagulation parameters (Prothrombin Time/INR) is still advised when the two are used together.
Other Medications	Prednisone, Theophylline, Digoxin	Official studies show that Montelukast has no clinically significant effect on the pharmacokinetics of these specific drugs and no interaction-related constraints are specified for their co-administration.

Procedural Constraints: The chewable tablet formulation contains phenylalanine and is contraindicated in patients with phenylketonuria (PKU). This constraint is based on a component-specific interaction with this patient population.

Mechanism of Action

Monteka acts as a Leukotriene Receptor Antagonist, modulating inflammatory pathways at the cellular level. The mechanism is highly specific and results in a physiological effect that reduces CysLT-mediated signaling.

Selective Blockade of the CysLT1 Receptor

The drug acts by binding with high affinity to the Cysteinyl Leukotriene Type 1 receptor ( CysLT1), found on airway smooth muscle and inflammatory cells. This interaction creates a competitive blockade that prevents the body's natural inflammatory signals—the cysteinyl leukotrienes ( LTD4, LTC4, LTE4)—from initiating their biological effects. As a result, the drug interrupts the leukotriene signaling cascade without activating the receptor itself.

Physiological Consequences of Receptor Blockade

By neutralizing the CysLT1 receptor, the mechanism produces three primary physiological consequences in the respiratory system. First, it prevents smooth muscle contraction and LTD4-induced bronchospasm. Second, it reduces vascular permeability, which limits CysLT-mediated airway edema (swelling) and mucus secretion. Third, it interferes with the signals that promote the recruitment and infiltration of inflammatory cells like eosinophils into the airways. This action provides a sustained blockade of the leukotriene signaling pathway.

Dosage and Administration Information

Administration and Dosing Principles

Monteka (Montelukast sodium) is administered exclusively via the oral route across all its approved formulations: film-coated tablets, chewable tablets, and oral granules. The approach to using the medication is standardized, requiring once-daily administration for chronic management.

Standard Daily Dosing Regimens

The numerical dose is strictly dependent on age and the therapeutic purpose. The fixed dosage strengths are not subject to titration and are summarized below:

Population	Official Dose (Once Daily)
Adults & Adolescents (ge 15 years)	10 mg
Children (6–14 years)	5 mg (Chewable Tablet)
Children (2–5 years)	4 mg (Chewable Tablet or Granules)

Frequency and Context of Use

The standard frequency for all indications is once daily. For the chronic treatment of asthma, the daily dose is consistently administered in the evening. When used for isolated allergic rhinitis, the timing is more flexible, allowing administration in the morning or evening. The medicine may be taken with or without food.

Specific procedural rules apply to the oral granules: they must be administered either directly or mixed with breast milk, formula, or specific soft foods (such as applesauce or rice). The full dose must be consumed within 15 minutes of opening the packet; the preparation cannot be stored.

No dosage adjustment is required for older adult patients, nor for those with mild-to-moderate renal or hepatic impairment. Furthermore, only one dose of Monteka is permitted per 24-hour period, regardless of the number of indications being treated.

Recent Clinical Evidence

Monteka: Recent Clinical Evidence

Summary of Research Focus

Research has explored various endpoints related to Monteka's use and focused on metrics relevant to patient status in key areas. Clinical trials typically measure outcomes such as the severity of symptoms, quality of life, and the frequency of disease flare-ups.

Large-Scale Randomized Trials

One large-scale trial reported findings relevant to changes in symptom severity over a 12-week period. The primary endpoint measured was the change from baseline on a validated Symptom Score (VSS). A separate trial of similar size examined whether combination therapy differed from monotherapy.

Studies on Process

Research examined the relationship between the drug and reported pain levels. This research involved the study of biochemical processes. A smaller Phase II study evaluated markers of inflammation in serum samples from participants.

Safety and Tolerability Profile

Clinical trials evaluated the side-effect profile of this treatment. Commonly reported adverse events in studies included mild headache and temporary nausea.

Drug Interactions Evaluated

Research evaluated the concurrent use of this with alcohol. Findings have included reports of dizziness. Studies also examined potential interactions with certain classes of over-the-counter pain medications.

Contraindication and Exclusion Criteria

Studies excluded people with condition X.

Comparative Research

Studies compared the absorption of this formulation with older versions, analyzing the time to peak plasma concentration (Tmax) and the total drug exposure (AUC). Research has examined the medication’s role in managing acute flare-ups.

Frequently Asked Questions (FAQ)

Common questions about Monteka (FAQ)

Q: Can Monteka be used to stop an asthma attack that is already happening?

Regulatory documents state that Monteka (Montelukast) is intended for the long-term control and prevention of symptoms. It is not indicated and must not be used to treat an acute asthma attack or difficulty breathing that is already occurring. The medication is not intended to replace quick-relief medicines for immediate symptom relief.

Q: Is it safe to take Monteka with common over-the-counter allergy medicines?

Official drug interaction studies for Monteka have focused on specific medicines that may affect its metabolism. The regulatory labeling does not specify any interaction constraints with many common non-prescription allergy medications. Patients with concerns about combining Monteka with other products are advised to consult official resources or a healthcare professional.

Q: Can Monteka cause changes in mood or sleep patterns?

Official regulatory labeling includes specific warnings regarding serious neuropsychiatric events that have been reported in all age groups. These events can include changes in mood and behavior, such as agitation, depression, aggression, and sleep disturbances, including difficulty sleeping and nightmares. These effects are part of the officially reported safety information.

Q: What are the most commonly reported mild side effects of Monteka?

The most frequently reported adverse reaction, classified as Very Common (at least 1 in 10 individuals), is an upper respiratory infection. Other common adverse reactions (at least 1 in 100 individuals) listed in the official product information include headache, abdominal pain, fever, nausea, vomiting, diarrhea, and rash.

Q: How long does it take to see the full benefits of Monteka for asthma control?

Pharmacological studies indicate that the medicine begins to act relatively quickly, with therapeutic effects demonstrated as soon as two hours after the first dose. Regulatory summaries note that if initial response is unsatisfactory, reassessment of therapy may occur after a continuous period of use, typically 4 to 8 weeks.

Q: What studies support the use of Monteka for preventing asthma symptoms?

Regulatory documents summarize evidence drawn from large-scale randomized trials. These studies have measured various clinical outcomes, including changes in symptom severity, improvements in quality of life, and the frequency of disease flare-ups over defined treatment periods.

Q: Why do some people with asthma take Monteka along with an inhaled steroid?

Monteka acts as a Leukotriene Receptor Antagonist—a different mechanism from inhaled steroids. Regulatory documents mention that it may be used in combination therapy as an added controller option, due to its distinct, complementary action in reducing inflammatory signaling pathways in the airways.

Q: Are vivid dreams or nightmares a common side effect of Monteka?

Vivid dreams and nightmares are listed in official regulatory warnings as potential neuropsychiatric events. These effects are considered possible adverse reactions, particularly in children, and are grouped with other reported sleep disturbances associated with the use of the medicine.

Q: Is there a generic version of Monteka available?

Yes. The active ingredient in Monteka is Montelukast sodium, which is available in generic formulations. The availability of generic options is a matter of public regulatory record following the expiration of the original patent.

Q: Is Monteka safe for use in toddlers or infants?

Official labeling specifies minimum age eligibility for treatment. For chronic asthma, the minimum age is 12 months and older. For perennial allergic rhinitis, the medication is eligible for patients 6 months of age and older.

Q: Are there any specific warnings for people with a history of mental health conditions before starting Monteka?

Official labeling advises consulting a healthcare professional regarding any history of mental health conditions before starting treatment. Official reports indicate that neuropsychiatric events have occurred in patients with and without pre-existing psychiatric disease, making this history a key consideration.

Q: Are there any known interactions between Monteka and alcohol?

Official prescribing information does not list a direct drug interaction with alcohol. However, reports of liver injury have been associated with its use, particularly in patients with other risk factors such as alcohol use.

Q: Does Monteka lose its effectiveness over time if taken daily?

Clinical trials have evaluated the effectiveness of continuous Monteka treatment over specific periods, such as 12 weeks. Evidence summarized in official documents found no evidence of tolerance or loss of protective effect over the duration of those studies.

Q: What should I do if my symptoms get worse after starting Monteka?

If new or worsening neuropsychiatric symptoms, or a significant change in behavior or mood are experienced, regulatory warnings indicate that consultation with a healthcare professional, including consideration of discontinuation, is appropriate.

Q: Is Monteka safe for someone who has liver problems?

Official labeling states that no dosage adjustment is required for patients with mild-to-moderate hepatic (liver) impairment. However, regulatory documents also note that the pharmacokinetics (how the drug moves through the body) have not been evaluated in patients with more severe hepatic impairment or active hepatitis.

Q: How long after stopping Monteka will it take for the drug to be completely out of my system?

Pharmacokinetic data available in official documents indicates that the mean plasma half-life of Montelukast—the time it takes for half the drug to be eliminated from the body—ranges from approximately 2.7 to 5.5 hours in healthy adults.

Q: Does Monteka help reduce the need for my rescue inhaler?

Studies summarized in regulatory reviews show that Monteka’s role as a long-term controller can lead to improved respiratory stability. Clinical trials focused on asthma and exercise-induced breathing difficulty have reported that patients taking this medication needed rescue beta2-agonists less often than those taking a placebo.

Q: Is Monteka associated with any risk of severe allergic reactions?

The medicine is contraindicated in patients with known hypersensitivity or allergy to the active ingredient, Montelukast, or to any of the components in the formulation. Severe allergic reactions such as anaphylaxis are reported in official post-marketing safety data.

Q: Is it safe for older adults (seniors) to take Monteka?

Regulatory assessment confirms that the pharmacokinetic profile (how the drug is absorbed and eliminated) is similar in older and younger adults. Official administration and dosing principles state that no dosage adjustment is required for older adult patients.

Q: Can I take Monteka if I am allergic to ingredients other than the main drug?

The medicine is officially contraindicated in patients with known hypersensitivity to the active ingredient, Montelukast, or to any of the inactive components (excipients) in the formulation. This constraint is outlined in the official product information.

Q: Can I take Monteka on the same day as my exercise dose?

Official administration instructions are clear that only one dose of Montelukast is permitted per 24-hour period, regardless of the indication being treated. The dose taken for exercise-induced bronchoconstriction is not to be taken within 24 hours of the regular daily dose.

How should Monteka be stored and disposed of?

Storage and Disposal of Montelukast Sodium

Montelukast sodium (Monteka) must be stored under specific conditions to maintain product stability and effectiveness, as defined by regulatory labeling.

Official Storage Requirements

Element	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F).
Protection	Must be stored in the original container to protect it from light and moisture.
Handling	Keep out of the reach of children.
Granules Stability	Oral granule doses must be administered within 15 minutes of mixing; do not store the mixed product.

Regulatory Disposal Instructions

Unused or expired product should be disposed of in accordance with local regulations. The U.S. FDA recommends utilizing drug take-back programs. The medication is not on the list of products recommended for disposal by flushing down the sink or toilet.

Monteka